GLUE

In September 2026, Monte Rosa Therapeutics announced a milestone achievement with the initiation of a Phase 2 clinical study for VAV1-directed Molecular Glue Degrader MRT-6160, triggering a $50 million milestone payment from Novartis, which also started a Sjögren's drug trial with Monte Rosa. In August 2026, the company reported inducement grants, participated in investor conferences, and posted its Q2 2026 net loss on a revenue drop, detailing its Q2 loss and cash runway. In July 2026, Monte Rosa Therapeutics announced the first patient dosed in MODeFIRe-1, a Phase 2 study of MRT-2359 in combination with apalutamide for metastatic prostate cancer. In May 2026, the company released its Q1 2026 earnings. In January 2026, Monte Rosa Therapeutics announced positive interim Phase 1 data for MRT-8102, demonstrating profound CRP reductions in subjects with elevated cardiovascular disease risk, which was associated with a significant daily stock move of +45.4%. Over the past 12 months, the stock price has gained 93.3%.